Guhyun Kang1, Byeong Seok Sohn2, Jung-Soo Pyo3, Jung Yeon Kim1, Boram Lee4, Kyoung-Mee Kim5. 1. Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. 2. Department of Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. 3. Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Ilwon-ro, Gangnam-gu, Seoul, 06351, Korea. 5. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Ilwon-ro, Gangnam-gu, Seoul, 06351, Korea. kkmkys@skku.edu.
Abstract
INTRODUCTION: Assessment of KIT/PDGFRA mutations is essential for therapeutic decision making in patients with gastrointestinal stromal tumor (GIST). Blood-derived circulating tumor DNA can provide molecular information representative of the tumor tissue. METHODS: In this study, primary tumors and matched presurgical blood samples were collected from 25 patients with localized gastric GIST, and the DNAs were analyzed for KIT and PDGFRA mutations using a next-generation sequencing platform. RESULTS: Sequencing of the tumors identified mutations in KIT exon 11 in 18/25 cases (72 %). The mutations were detected in 13/18 (72 %) plasma samples from the patients harboring KIT mutation in the paired GIST tissue. Identical point mutations were found in three of the presurgical plasma samples, and insertion/deletions were detected as single-base substitutions in ten cases. No mutations were detected in plasma samples from the seven patients with KIT/PDGFRA wild-type GIST. CONCLUSION: Our study demonstrates that primary KIT mutations can be detected in the presurgical plasma of patients with localized GIST; this would help clinicians reach proper diagnoses before surgery and assist them to make appropriate therapeutic decisions.
INTRODUCTION: Assessment of KIT/PDGFRA mutations is essential for therapeutic decision making in patients with gastrointestinal stromal tumor (GIST). Blood-derived circulating tumor DNA can provide molecular information representative of the tumor tissue. METHODS: In this study, primary tumors and matched presurgical blood samples were collected from 25 patients with localized gastric GIST, and the DNAs were analyzed for KIT and PDGFRA mutations using a next-generation sequencing platform. RESULTS: Sequencing of the tumors identified mutations in KIT exon 11 in 18/25 cases (72 %). The mutations were detected in 13/18 (72 %) plasma samples from the patients harboring KIT mutation in the paired GIST tissue. Identical point mutations were found in three of the presurgical plasma samples, and insertion/deletions were detected as single-base substitutions in ten cases. No mutations were detected in plasma samples from the seven patients with KIT/PDGFRA wild-type GIST. CONCLUSION: Our study demonstrates that primary KIT mutations can be detected in the presurgical plasma of patients with localized GIST; this would help clinicians reach proper diagnoses before surgery and assist them to make appropriate therapeutic decisions.
Authors: Julia A Beaver; Danijela Jelovac; Sasidharan Balukrishna; Rory Cochran; Sarah Croessmann; Daniel J Zabransky; Hong Yuen Wong; Patricia Valda Toro; Justin Cidado; Brian G Blair; David Chu; Timothy Burns; Michaela J Higgins; Vered Stearns; Lisa Jacobs; Mehran Habibi; Julie Lange; Paula J Hurley; Josh Lauring; Dustin VanDenBerg; Jill Kessler; Stacie Jeter; Michael L Samuels; Dianna Maar; Leslie Cope; Ashley Cimino-Mathews; Pedram Argani; Antonio C Wolff; Ben H Park Journal: Clin Cancer Res Date: 2014-02-06 Impact factor: 12.531
Authors: Christopher L Corless; Arin Schroeder; Diana Griffith; Ajia Town; Laura McGreevey; Patina Harrell; Sharon Shiraga; Troy Bainbridge; Jason Morich; Michael C Heinrich Journal: J Clin Oncol Date: 2005-05-31 Impact factor: 44.544
Authors: Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: Pieter A Boonstra; Jourik A Gietema; Albert J H Suurmeijer; Matthew R Groves; Fernando de Assis Batista; Ed Schuuring; Anna K L Reyners Journal: Oncotarget Date: 2017-11-26
Authors: Pieter A Boonstra; Arja Ter Elst; Marco Tibbesma; Lisette J Bosman; Ron Mathijssen; Florence Atrafi; Frits van Coevorden; Neeltje Steeghs; Sheima Farag; Hans Gelderblom; Winette T A van der Graaf; Ingrid M E Desar; Jacqueline Maier; Jelle Overbosch; Albert J H Suurmeijer; Jourik Gietema; Ed Schuuring; Anna K L Reyners Journal: Oncotarget Date: 2018-02-14
Authors: César Serrano; Ana Vivancos; Antonio López-Pousa; Judit Matito; Francesco M Mancuso; Claudia Valverde; Sergi Quiroga; Stefania Landolfi; Sandra Castro; Cristina Dopazo; Ana Sebio; Anna C Virgili; María M Menso; Javier Martín-Broto; Miriam Sansó; Alfonso García-Valverde; Jordi Rosell; Jonathan A Fletcher; Suzanne George; Joan Carles; Joaquín Arribas Journal: BMC Cancer Date: 2020-02-05 Impact factor: 4.430